Recurrent Childhood Small Noncleaved Cell Lymphoma [clinicaltrials_resource:498b4cb1758de0034f18307a7ad77586]
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment [clinicaltrials:NCT00005811]Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer [clinicaltrials:NCT00006251]Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas [clinicaltrials:NCT00012181]Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT00014235]Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma [clinicaltrials:NCT00036855]Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies [clinicaltrials:NCT00040846]clinicaltrials:NCT00049504Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia [clinicaltrials:NCT00058461]Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant [clinicaltrials:NCT00078858]Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00089011]Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [clinicaltrials:NCT00101205]Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas [clinicaltrials:NCT00101270]Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [clinicaltrials:NCT00118352]Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia [clinicaltrials:NCT00217412]clinicaltrials:NCT00309907Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma [clinicaltrials:NCT00363272]Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease After Donor Stem Cell Transplant [clinicaltrials:NCT00408681]Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma [clinicaltrials:NCT00458731]High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors [clinicaltrials:NCT00536601]Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant [clinicaltrials:NCT00795769]Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders [clinicaltrials:NCT00856388]Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [clinicaltrials:NCT00867529]Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia [clinicaltrials:NCT00933985]Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma [clinicaltrials:NCT00994500]Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer [clinicaltrials:NCT01053494]Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia [clinicaltrials:NCT01088763]Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01093586]Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant [clinicaltrials:NCT01231412]MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia [clinicaltrials:NCT01231919]Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant [clinicaltrials:NCT01251575]Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant [clinicaltrials:NCT01305200]Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies [clinicaltrials:NCT01427881]Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01529827]MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [clinicaltrials:NCT01748721]clinicaltrials:NCT01760655Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01839916]Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant [clinicaltrials:NCT01959477]
condition [clinicaltrials_vocabulary:condition]
Recurrent Childhood Small Noncleaved Cell Lymphoma [clinicaltrials_resource:498b4cb1758de0034f18307a7ad77586]
Bio2RDF identifier
498b4cb1758de0034f18307a7ad77586
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:498b4cb1758de0034f18307a7ad77586
identifier
clinicaltrials_resource:498b4cb1758de0034f18307a7ad77586
title
Recurrent Childhood Small Noncleaved Cell Lymphoma
@en
label
Recurrent Childhood Small Nonc ...... b4cb1758de0034f18307a7ad77586]
@en